120 related articles for article (PubMed ID: 15041403)
1. FTY720: early clinical experience.
Dragun D; Fritsche L; Boehler T; Peters H; Budde K; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):544S-548S. PubMed ID: 15041403
[TBL] [Abstract][Full Text] [Related]
2. FTY720 immunomodulation: optimism for improved transplant regimens.
Ferguson R
Transplant Proc; 2004 Mar; 36(2 Suppl):549S-553S. PubMed ID: 15041404
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Kahan BD; Karlix JL; Ferguson RM; Leichtman AB; Mulgaonkar S; Gonwa TA; Skerjanec A; Schmouder RL; Chodoff L
Transplantation; 2003 Oct; 76(7):1079-84. PubMed ID: 14557756
[TBL] [Abstract][Full Text] [Related]
4. FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A.
Koshiba T; Van Damme B; Rutgeerts O; Waer M; Pirenne J
Transplantation; 2003 Apr; 75(7):945-52. PubMed ID: 12698078
[TBL] [Abstract][Full Text] [Related]
5. A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments.
Suzuki T; Jin MB; Shimamura T; Yamashita K; Taniguchi M; Nomura M; Yokota R; Fukai M; Magata S; Horiuchi H; Fujita M; Nagashima K; Furukawa H; Todo S
Transpl Int; 2004 Nov; 17(10):574-84. PubMed ID: 15592714
[TBL] [Abstract][Full Text] [Related]
6. FTY720 in combination with cyclosporine--an analysis of skin allograft survival and renal function.
Silva FR; Silva LB; Cury PM; Burdmann EA; Bueno V
Int Immunopharmacol; 2006 Dec; 6(13-14):1911-8. PubMed ID: 17161344
[TBL] [Abstract][Full Text] [Related]
7. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
Tedesco-Silva H; Mourad G; Kahan BD; Boira JG; Weimar W; Mulgaonkar S; Nashan B; Madsen S; Charpentier B; Pellet P; Vanrenterghem Y
Transplantation; 2004 Jun; 77(12):1826-33. PubMed ID: 15223899
[TBL] [Abstract][Full Text] [Related]
8. FTY720 (fingolimod) in renal transplantation.
Budde K; Schütz M; Glander P; Peters H; Waiser J; Liefeldt L; Neumayer HH; Böhler T
Clin Transplant; 2006; 20 Suppl 17():17-24. PubMed ID: 17100697
[TBL] [Abstract][Full Text] [Related]
9. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
[TBL] [Abstract][Full Text] [Related]
11. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.
Skerjanec A; Tedesco H; Neumayer HH; Cole E; Budde K; Hsu CH; Schmouder R
J Clin Pharmacol; 2005 Nov; 45(11):1268-78. PubMed ID: 16239360
[TBL] [Abstract][Full Text] [Related]
12. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
[TBL] [Abstract][Full Text] [Related]
13. Rejection following donor or recipient preoperative treatment with FTY720 in rat small bowel transplantation.
Sakagawa T; Kiyochi H; Honda K; Kobayashi N
Transpl Immunol; 2004 Nov; 13(3):161-8. PubMed ID: 15381198
[TBL] [Abstract][Full Text] [Related]
14. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
Kovarik JM; Schmouder RL; Barilla D; Büche M; Rouilly M; Berthier S; Wang Y; Van Saders C; Mayer T; Gottlieb AB
Ann Pharmacother; 2004; 38(7-8):1153-8. PubMed ID: 15138297
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.
Meno-Tetang GM; Li H; Mis S; Pyszczynski N; Heining P; Lowe P; Jusko WJ
Drug Metab Dispos; 2006 Sep; 34(9):1480-7. PubMed ID: 16751263
[TBL] [Abstract][Full Text] [Related]
16. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice.
Lopes CT; Gallo AP; Palma PV; Cury PM; Bueno V
Transplant Proc; 2008 Apr; 40(3):856-60. PubMed ID: 18455036
[TBL] [Abstract][Full Text] [Related]
17. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts.
Shimizu H; Takahashi M; Kaneko T; Murakami T; Hakamata Y; Kudou S; Kishi T; Fukuchi K; Iwanami S; Kuriyama K; Yasue T; Enosawa S; Matsumoto K; Takeyoshi I; Morishita Y; Kobayashi E
Circulation; 2005 Jan; 111(2):222-9. PubMed ID: 15642767
[TBL] [Abstract][Full Text] [Related]
18. FTY720: from bench to bedside.
Kahan BD
Transplant Proc; 2004 Mar; 36(2 Suppl):531S-543S. PubMed ID: 15041402
[TBL] [Abstract][Full Text] [Related]
19. FTY720, a new immunosuppressant, as rescue therapy in mouse cardiac transplantation.
Wang MH; Milekhin V; Zhang H; Huang HZ
Acta Pharmacol Sin; 2003 Sep; 24(9):847-52. PubMed ID: 12956930
[TBL] [Abstract][Full Text] [Related]
20. FTY720 treatment prolongs skin graft survival in a completely incompatible strain combination.
Lima RS; Nogueira-Martins MF; Silva HT; Pestana JO; Bueno V
Transplant Proc; 2004 May; 36(4):1015-7. PubMed ID: 15194353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
